The ministry said that 12,76,191 doses were given only on Friday - the 77th day of the countrywide vaccination drive - as India registered the highest single-day rise in new infections in the last six months.
First author on the paper, Dr Helen Parry, a National Institute for Health Research academic clinical lecturer at the University of Birmingham, said: "Our research provides further evidence that the mRNA vaccine platform delivers a strong immune antibody response in people up to 96 years of age and retains broad efficacy against the P.1 (Brazilian) variant, which is a variant of concern".
"We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year", said Pfizer chief executive Albert Bourla.
The release of updated results comes on the heels of separate data that showed the vaccine is safe and effective in 12 to 15-year-olds, paving the way for the drugmakers to seek U.S. and European approval to use the shot in this age group within weeks.
It comes as a separate UK-based study found the Pfizer vaccine produces an "off the scale" immune response that is likely to protect against the Brazilian variant of Covid-19, with scientists in the United Kingdom reporting strong immune responses in older people who had received two shots of the Pfizer vaccine. It more than likely will be even longer.
The shot was also 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is dominant, though the number of those participants was relatively small at 800.
Pfizer CFO Frank D'Amelio said that the COVID-19 vaccine might have to shift gears if the virus becomes endemic to our society.
The company has been studying the vaccine in more than 46,000 volunteers and has noted 927 cases of confirmed COVID-19.
Earlier this week, Pfizer/BioNTech had hopeful results from a vaccine trial in children between 12 and 15 years old.
"The antibody levels were so high that they'd gone above the thresholds so they had to dilute them".
'I would not be surprised if this is a vaccine that we only get once'.
The vaccine was 100% effective in preventing severe disease as defined by the US Centres for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the US Food and Drug Administration. As part of the process, they both must continue their clinical trials for two years and will continue to report safety and efficacy data as they get it.
Fully vaccinated can travel again, says new CDC guidance
Plus, almost all worldwide US air visitors still need to get a negative Covid-19 test before traveling to the United States. A person is considered fully vaccinated two weeks after receiving the last recommended dose of vaccine, the CDC said.
Man rams vehicle into police officers near US Capitol
This time, one officer was killed and a second hospitalized after a driver rammed a security checkpoint on the Capitol grounds. One person has died after slamming a vehicle into the security barrier surrounding the Capitol building, U.S. media report .